STOCKS TELEGRAPH

Tag: EARS

  • Auris Medical Holding Ltd. (EARS) stock is Popping high today: What’s Going on?

    Auris Medical Holding Ltd. (EARS) stock is Popping high today: What’s Going on?

    Auris Medical Holding Ltd. (EARS) stock announced positive results of its in vivo study of OligoPhoreTM technology in adults after which the EARS stock price saw an uptrend of 9.04% to reach $3.62 a share at the time of this writing. It seems that momentum was already built in the previous session as EARS went up by 0.61% at closing. Let’s deeply discuss the EARS stock.

    OligoPhoreTM siRNA Study:

    Investors are responding positively to the announcement by EARS stock on June 21, 2021, according to which EARS’ OligoPhoreTM siRNA targeting the NF-κBinAdult T-cell Leukemia Lymphoma (ATLL) has significantly refrained the tumor growth. The research groups jointly conducted the study at the University of South Florida, Tampa FL, and the Washington University, St. Louis MO. The RNA nanoparticles were developed and evaluated by researchers of the study. In this process, two NF-κB signaling pathways were targeted by siRNA and peptide carrier of Auris’s OligoPhoreTM. The research groups administered siRNA nanoparticles to two mice groups with either tumor cell transplantation or ATLL tumor growth.

    Study Results:

    The study showed positive results as siRNA delivered rapidly to the tumor and target mRNA and protein expression had been significantly reduced which resulted the inhibit tumor growth. Tumor size, spleen size and peripheral blood lymphocyte counts were reduced significantly in the mice participated in the study as compared to control and the most aggressive tumors showed nearly zero growth.

    Acquisition of Trasir Therapeutics, Inc:

    On June 03, 2021, Auris stock entered the field of RNA therapeutics via the acquisition of Trasir Therapeutics, Inc , which is a private company in Tampa, FL famous for extrahepatic oligonucleotide delivery. The purchase price for this acquisition was $0.77 million common shares of EARS stock. The transaction was closed on June 1, 2021. The Trasir’s founder, Dr. Samuel Wickline joined the EARS’ leadership team by taking the role of Chief Scientific Officer.

    Repositioning of EARS stock:

    The Auris Medical initiated its repositioning via the acquisition of Trasir Therapeutics and aims to develop RNA therapeutics in the future amid spinning off existing assets in neurotology, rhinology, and allergology. EARS board of directors proposed a change in corporate name to Altamira Therapeutics Ltd in order to reflect the strategic repositioning. The shares will start to trade under the ticker symbol CYTO upon regulatory approvals.

    Conclusion:

    So far so good for Auris Medical stock as far as market sentiment is concerned due to the release of positive in vivo results of OligoPhoreTM siRNA Study by EARS stock. The management is focused in the repositioning of the company and planning to grow via the development of RNA therapeutics. In a nutshell, this stock can prove to be fruitful in the long run.

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.

  • Auris Medical (EARS) Shares Quadruples on Positive Data of AM-301

    Auris Medical (EARS) Shares Quadruples on Positive Data of AM-301

    The Bermuda-based clinical-stage firm reports strong results from its drug-free nasal spray AM-301. The nasal spray results show potential for AM-301 to alleviatethe risk of Sars-CoV-2 virus.

    The last month of 2020 brings good news for the clinical-stage company, Auris Medical Holding Ltd. (EARS). The company reported that it has achieved positive efficacy data from clinical testing of AM-301 in vitro.

    The positive results of AM-301 have turned many investors towards the stock market to invest in EARS. Auris shares were trading at $1.11 in the previous trading session and investors saw great potential in $1 dollar stock to go big in long-term with potential nasal spray AM-301.

    EARS started the session at $1.46 as it continued to quadruple trading at $5.72. The shares have added +$4.61 surging up to 415.02% as of 11:57 A.M. EST. The trading volume is above 164 million compared to the average volume of 2.1 million.

    AM-301 is a drug-free nasal spray that was developed to prevent airborne pathogens and allergens. The company after testing AM-301 in vitro found out that it can be helpful in blocking Sars-CoV-2, the virus that causes COVID-19. The nasal spray forms a protective gel layer on the nasal mucosa that stops viruses to contact cells, saving from viral infections such as pathogens and allergens.

    AM-301 was tested for its potential to block the SARS-CoV-2 virus of nasal epithelial cells. These cells are sensitive to inhaled substances such as pathogens and allergens.

    Auris Medical’s affiliate Altamira Medica is developing the nasal spray AM-301.The efficacy data showed up to 99.4% reduction of viral titer in human epithelial cell culture.

    The company reported that daily treatment with AM-301 reflected healthy and efficient outcomes in protecting against viral infections. The average virus titers were 90% lower after 48 hours post-infection. Following 72- and 96-hours post-infection, the average virus titers reduced up to 99.2% and 99.4%.

    The company performed this testing in a four days period on reformed human nasal epithelia. The treatment was effective against Sars-CoV-2 in saline-treated control societies.

    The CEO and founder of Auris Medical, Thomas Meyer highlighted that their newly created spray formulationhas shown direct evidence for AM-301 to protect and limit the risk of nasal mucosal cell infection.

    Auris Medical Holding Ltd. (EARS)is looking forward to containing additional testing and apply for regulatory approval in the coming year.